NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness ...
CNET staff -- not advertisers, partners or business interests -- determine how we review products and services. If you buy through our links, we may earn a commission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback